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Abstract
Wnt signaling is a critical regulatory pathway in development and disease. Very little is known about the mechanisms of Wnt
signaling in prostate cancer, a leading cause of death in men. A quantitative analysis of the expression of Wnt5A protein in
human tissue arrays, containing 600 prostate tissue cores, showed .50% increase in malignant compared to benign cores
(p,0.0001). In a matched pair of prostate cancer and normal cell line, expression of Wnt5A protein was also increased.
Calcium waves were induced in prostate cells in response to Wnt5A with a 3 fold increase in Flou-4 intensity. The activity of
Ca
2+/calmodulin dependent protein kinase (CaMKII), a transducer of the non-canonical Wnt/Ca
2+ signaling, increased by 8
fold in cancer cells; no change was observed in b-catenin expression, known to activate the canonical Wnt/b-catenin
pathway. Mining of publicly available human prostate cancer oligoarray datasets revealed that the expression of numerous
genes (e.g., CCND1, CD44) under the control of b-catenin transcription is down-regulated. Confocal and quantitative electron
microscopy showed that specific inhibition of CaMKII in cancer cells causes remodeling of the actin cytoskeleton, irregular
wound edges and loose intercellular architecture and a 6 and 8 fold increase in the frequency and length of filopodia,
respectively. Conversely, untreated normal prostate cells showed an irregular wound edge and loose intercellular
architecture; incubation of normal prostate cells with recombinant Wnt5A protein induced actin remodeling with a regular
wound edge and increased wound healing capacity. Live cell imaging showed that a functional consequence of CaMKII
inhibition was 80% decrease in wound healing capacity and reduced cell motility in cancer cells. We propose that non-
canonical Wnt/Ca
2+ signaling via CaMKII acts as a novel regulator of structural plasticity and cell motility in prostate cancer.
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Introduction
Wingless/Wnt genes code for a family of secreted glycoproteins
that regulate many cellular processes [1,2]. Aberrant signaling
through Wnt signaling pathways is linked to a number of diseases
including cancer [3–6]. Wnt signaling occurs via the canonical
(Wnt/b-catenin, CTNNB1) and non-canonical (Wnt/Ca
2+)p a t h -
ways [3,7]. A less well described Wnt pathway is the Wnt-JNK
pathway [8]. Signaling via the Wnt/b-catenin pathway activates
transcription of many genes, such as cyclin Ds and membrane
metalloproteinases (MMPs), via TCF/LEF factors. Wnt/Ca
2+
pathway leads to an increase in intracellular calcium [9] and
activation of calmodulin dependent protein kinase II (CaMKII) [10]
and is known to modulate cell movement and behavior [11,12] and
induces structural changes [11,13,14]. The link between increased
b-catenin signaling in tumorigenesis and increased transcription of
genes involved in cell transformation and proliferation are
documented, however, the role non-canonical Wnt/Ca
2+ signaling
in cancer is only slowly being elucidated [15,16].
Prostate cancer accounts for an estimated 25% of all new cancer
cases and is the second leading cause of cancer deaths in males [17].
Neither the expression of Wnt proteins nor the mechanisms of Wnt
signaling in prostate cancer are understood [18]. Previous studies
concentrated on characterization of Wnt receptors, receptor related
proteins and expression of Wnt genes [5,19–21], in prostate cancer
cell lines. Direct interaction between androgen receptor (AR) and
TCF for b-catenin and other transcription co-factors was also
suggested [22]. However, only a small percentage of prostate cancer
samples have dysregulated destruction complex or mutated b-
catenin [18]. It is likely therefore that other mechanisms, perhaps
directly linked to Wnt signaling, may be involved.
We recently showed [23] that WNT5A (one of the 19 members
of Wnt family) gene expression is increased (.50 fold) in prostate
cancer tissue and cancer cell lines due to hypomethylation.
However, important questions regarding Wnt5A expression and
the mechanisms of Wnt5A mediated signaling in prostate cancer
remain. For example, we do not know (i) Whether the increase in
WNT5A gene transcription results in increased Wnt5A protein
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non-canonical signaling pathway is activated in prostate cancer?
(iii) What is the functional role of Wnt signaling in prostate cancer?
To address these questions we tested the following hypotheses: (i)
That Wnt5A protein expression is increased in human prostate
cancer (ii) That Wnt/b-catenin signaling should result in increased
expression of TCF/LEF target genes such as MMPs and TIMP3
in prostate cancer (iii) Activation of Wnt/Ca
2+ signaling in
prostate cancer cells should result in an increase in CaMKII
enzyme activity causing alterations in cytoskeleton and cell
motility. We show, for the first time, that Wnt5A protein
expression is increased in malignant human prostate compared
to benign tissue and Wnt/Ca
2+ signaling mechanism is activated
in prostate cancer cells. We also provide novel mechanistic
evidence of a critical role for CaMKII as a modulator of actin
cytoskeleton and cell motility in prostate cancer.
Results
RNA transcript assessment using real time PCR
We measured the mRNA levels for WNT5A (Table S1),
previously identified from our oligoarray analysis to be dysregu-
lated in prostate cancer cells [23]. WNT5A mRNA displayed a
similar magnitude of change (,50 fold) in 1542-CP3TX cancer
cells compared to normal 1542-NPTX cells, whether measured
using oligoarray [23] or real time PCR (Table S1). WNT5A
transcript is also expressed in other prostate cancer cell lines e.g.
PC3 and DU145 [19,23].
Wnt5A protein expression in malignant and benign
human prostate
3,3-diaminobenzidine (DAB) label, representing Wnt5A expres-
sion, was observed in both malignant and benign tissue cores
(Fig. 1A and B). We quantified the label, in an unbiased manner,
by using a reproducible, semi-automated particle analysis (Analyze
Particles) protocol using ImageJ software [24] after converting
RGB images into 16 bit grayscale (Fig 1C and D) from 600
individual prostate tissue cores (see Materials and Methods).
Calculated parameters of count, total area, average size and area
fraction are given in Table S2. Integration of area under the curve
revealed a 55%, 25% and 45% increase in the total area, average
size and area fraction (total area /total pixels), representing the
extent and intensity of staining, in malignant cores (n=301)
compared to benign cores (n=299), respectively (Fig 1E, F and G)
Figure 1. Wnt5A expression in malignant and benign human prostate tissue. Representative malignant (A) and benign (B) tissue core from
human prostate arrays used to calculate Wnt5A expression (DAB label, brown, largely in acinar cells). RGB images (A and B) were converted to 16 bit
images (C and D) for the quantification of the DAB signal using Analyze Particle protocol in ImageJ software to obtain Total Area stained (E) and
Average Size of the particle measured (F), in pixel, and Area Fraction (G, total area divided by the total pixels in the image). Wnt 5A expression was
increased in malignant v benign cores (p,0.0001). Each bin is data for an individual, malignant (red, n=301) or benign (green, n=299) core.
doi:10.1371/journal.pone.0010456.g001
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results indicate that Wnt5A expression is increased in malignant
compared to benign human prostate.
Mechanisms of Wnt-signaling in prostate cancer
Expression of Wnt5A protein was also higher in 1542-CP3TX
cancer cells compared to matched normal 1542-NPTX cells
(Fig. 2A). There was also a concomitant decrease (2.5 fold) in
mRNA transcript of CTNNB1 and other elements of Wnt/b-
catenin signaling (e.g. axin, DVL1, GSK3b) in cancer cells
compared to normal cells (Table S1). Antagonism of b-catenin due
to overexpression of Wnt5A, leading to downregulation of Wnt/b-
catenin target has been proposed previously in melanoma [25] and
Xenopus embryos [11]. b-catenin protein expression, using
Western blotting showed a single band (,94kDa) in a protein
concentration dependent manner, in cell lysates from both 1542-
CP3TX and 1542-NPTX cells (Fig. 2B). Densitometric analysis
showed that there was no change in b-catenin protein in the
cancer compared to normal cell line (Fig. 2C). Furthermore,
according to our oligoarray data [23] a number of Wnt/b-catenin
mediated TCF transcription target genes showed decreased
mRNA expression in cancer cells (Table S3). A detailed
examination at protein and functional level of selected targets of
TCF/LEF transcription (e.g. MMP2, MMP14 and TIMP3) [26]
confirmed these observations. mRNA expression for these genes
was 3–10 fold lower in cancer cells compared to normal cells
(Table S1) supported by indirect immunofluorescence (Fig. S1).
MMP-14 activity should reflect the equilibrium between MMP-14
catalytic and TIMP3 regulatory activities. MMP activity was
360.06 fold lower in the cancer cells using gelatin zymography
(Fig. S2). These results confirmed that numerous targets of Wnt/b-
catenin signaling pathway were down-regulated at gene, protein or
functional level.
Analysis of gene expression of CTNNB1 and TCF/LEF
transcription targets, using Oncomine [27] and GeneSpring
software and publicly available microarray datasets for normal
(non-neoplastic or benign) vs cancer prostate tissue, showed that
the expression of almost all Wnt/b-catenin/TCF targets analyzed,
except c-myc, was decreased in prostate cancer (Fig. S3). These
results are similar to those for prostate cell lines and demonstrate
that b-catenin mediated increase in TCF transcription was not
likely to be the mechanism of Wnt signaling in prostate cancer. We
therefore tested the hypothesis that in the prostate cancer, Wnt
signaling is transduced via Wnt/Ca
2+ pathway. We performed
experiments to establish if Wnt5A directly induced calcium release
in prostate cells. Addition of Wnt5A peptide induced calcium
waves, lasting upto 100s, in prostate cancer cell line with a
3.160.1 (n=12) fold increase in the intensity of Flou-4 from the
base line (Fig 3 and Movie S1).
CaMKII activity and its role in structural plasticity of
prostate cells
CamKII is a major transducer of Wnt/Ca
2+ signaling. In all
prostate cell lines CaMKII enzyme activity was Ca
2+ dependent,
least in 1542-NPTX, greater in 1542-CP3TX and DU145 and
pronounced in PC3 cell line (Fig. 4). There was a 4 and 8 fold
increase in the Ca
2+-dependent CaMKII activity in1542-NPTX
and 1542-CP3TX cells (Fig. 4), respectively. More importantly, the
Ca
2+ dependent activity of CaMKII was increased by ,4 fold in
1542-CP3TX compared to 1542-NPTX (inset Fig. 4). These results
indicate an increase in the activity of CaMKII in cancer cells
compared to normal cells.
To investigate the role of Wnt signaling in actin cytoskeleton of
normal and cancer prostate cells, we used a wound/scratch assay
in combination with confocal and scanning electron microscopy
and live cell imaging. Firstly, the leading edge of the wound was
observed for actin-remodeling, using confocal microscopy after
staining with fluorescently labelled phalloidin. In 1542-CP3TX
cells the leading edge of the wound, at 4 h post-wounding, showed
smooth, regular actin staining, with cells appearing in a
lamellipodia like formation (Fig. 5A). In 1542-NPTX cells the
leading edge of the wound was irregular with morphology of
individual cells, some with fine filopodia like structures visible at
4 h (Fig. 5B).
We next tested the following hypotheses: (i) inhibition of
CaMKII should disrupt the wound leading edge in prostate cancer
cell lines (ii) activation of Wnt5A signaling in 1542-NPTX cells
should promote actin remodeling of the wound as observed in
1542-CP3TX cells. We used myristoylated autocamtide-2-related
inhibitory peptide (AIP), an inhibitor of CaMKII, and recombi-
nant Wnt5A protein (to activate Wnt signaling) in normal and
cancer cells to test these hypotheses (Fig. 5). Confocal microscopy
of wounded/scratched monolayer of 1542-CP3TX cells incubated
with AIP (10 mM) displayed disrupted, irregular wound leading
Figure 2. Wnt5A expression in prostate cell lines. Western blot of
(A) Wnt5A protein expression, showing higher levels in 1542-CP3TX (CP)
cells compared to 1542-NPTX (NP) cells. b-actin was used as a loading
control. (B) b-catenin (94kDa) expression in cell lysate from 1542-CP3TX
and 1542-NPTX cell lines (GAPDH, 35kDa, used as a protein loading
control on the same blot). (C) Densitometric analysis was performed
using commercial software (GeneTools, Synoptics, UK). NP (filled bar) =
1542-NPTX and CP (hollow bar) =1542-CP3TX.
doi:10.1371/journal.pone.0010456.g002
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wound edge in untreated cells (Fig. 5A). The leading edge of
wounded 1542-NPTX cells with or without AIP showed an
irregular edge, with loose cell to cell contact and fine actin filament
protrusions (Fig. 5B and D). These micrographs indicate that
inhibition of CaMKII in 1542-CP3TX cancer cells induce
filopodia like protrusions. Conversely, wounded 1542-NPTX
normal cells, incubated with recombinant Wnt5A protein
(100 ng/ml), displayed a regular leading edge (Fig. 5E) of the
wound compared to the untreated control (Fig. 5B). No apparent
difference was observed in the leading wound edge for untreated
vs Wnt5A protein incubated 1542-CP3TX cells (Fig. 5A and F).
To validate that actin remodeling was mediated by CaMKII
and not via other kinases (e.g. CaMKIV, PKA, PKC, Raf or
MAPK1, JNK1a1, or Raf), we used tatCN21a, a specific inhibitor
of CamKII [28]. 1542-CP3TX cells treated with 5 mMo f
tatCN21a showed irregular wound edges, loose cell to cell contact
and filopodia formation (Fig. S4) as that observed with AIP (Fig. 5).
Inhibition of CaMKII also induced, irregular wound edge,
loosening of cell to cell contact and filopodia in other prostate
cancer cell lines including PC3 (Fig. 5G and H and Fig. S5),
DU145 (Fig. S6) and androgen sensitive LnCaP cell line (Fig. S7).
The mechanism by which CaMKII inhibition caused filopodia
formation in prostate cancer cells was next considered. We used
scanning electron microscopy to quantify the filopodia like
structures (Fig. 6). Low magnification scanning electron micro-
graphs of 1542-CP3TX cells show regular and irregular wound
leading edges in untreated (inset Fig. 6A) and AIP treated cells (inset
Fig. 6B). High magnification images clearly show numerous and
extended fine filopodia like projections from the cell membrane
(Fig. 6B) in AIP treated 1542-CP3TX cells compared to untreated
cells (Fig. 6A). Inhibition of CaMKII with AIP caused a similar
effect in PC3 cell line (Fig. 5H and Fig. S5B). The frequency and
length of the filopodia was measured manually using ImageJ
software. A Gaussian fit of the length distribution histogram of
treated and untreated 1542-CP3TX cells revealed an 8 fold
increase in the length and a 6 fold increase in the overall frequency
of filopodia like protrusions in AIP treated compared to untreated
1542-CP3TX cells (Fig. 6C and Table 1). The histogram could be
fitted for at least two lengths of filopodia like protrusions in 1542-
CP3TX cells: long (up to 2 mm) and very long (.2 mm). Further
analysis showed that there was a 5 fold increase in length but a
much greater (15 fold) increase in the frequency of the very long
protrusions in AIP treated cells compared to untreated cells
(Table 1). These results confirm a major role for CaMKII
mediated Wnt signaling in actin remodeling in prostate cancer by
decreasing the length and frequency of filopodia.
Figure 3. Wnt5A induces calcium release in prostate cancer
cells. A representative graph of calcium release in prostate cancer cell
line (PC3) as a function of Fluo-4 intensity change over time using
confocal live cell imaging. The green line represents the change in the
Fluo-4 intensity (green line) in (A) control (after addition of vehicle PBS)
or (B) recombinant Wnt5A peptide (100 ng/ml). There was a 3.160.1
fold increase in Fluo-4 intensity after addition of Wnt5A (n=12). In
some experiments Fura Red (red line) was loaded with Fluo-4. The ratio
of change in Fluo-4 and Fura-red is plotted in (C).
doi:10.1371/journal.pone.0010456.g003
Figure 4. CaMKII activity in prostate cells. The phosphotransferase
activity of CaMKII in cell lysates was measured by using a [c-
32P] ATP
based CaMKII assay (Upstate, UK) with Ca
2+ (hatched bars) or without
Ca
2+ (hollow bars). Inset:C a
2+-dependent CaMKII activity was calculated
as described in Materials and Methods. Values are mean 6 SE from 3
experiments. NP is1542-NPTX, CP is1542-CP3TX, DU is DU145 and PC is
PC3 prostate cell line.
doi:10.1371/journal.pone.0010456.g004
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2+ signaling in prostate
cancer cells
Cytoskeleton plays an integral role in cell motility. To
investigate the possible manifestations of cytoskeletal alterations
we tested the hypothesis that CaMKII inhibition will decrease cell
motility in prostate cancer cell lines. We used the wound scratch
assay and live cell imaging with Incucyte (Essen Instruments) to
calculate the rate of wound closure as a measure of cell motility.
The rate of wound closure was decreased by 80% in PC3 cancer
cell lines treated with AIP (Fig. 7 and Movie S2, control and
Movie S3, AIP).
Discussion
Wnt expression and mechanisms of Wnt signaling remains a
poorly investigated area in prostate. We demonstrate that (i)
Wnt5A protein expression is increased in malignant compared to
benign human prostate tissue and in cancer cell lines compared to
normal. (ii) Wnt5A is major transducer of Wnt signaling via
activation of Wnt/Ca
2+ pathway and not Wnt/b-catenin pathway
in prostate cells. (iii) Activation of CaMKII is a novel and critical
regulator of cytoskeleton in prostate cancer. (iv) CaMKII
inhibition significantly decreases cell motility and the capacity of
wound healing in prostate cancer cell lines.
An understanding of the molecular basis of prostate cancer, and
the role played by signaling networks such as Wnt-pathway,
requires not only a comprehensive description of gene and protein
expression in human prostate tissue, but also a cell system with
which to investigate the mechanisms of signaling and its functional
consequences in disease. Our prostate tissue array investigations
show that there was a highly significant (p,0.0001) increase in
both the total area (extent) and average size of the labelled
particles (intensity) and area fraction (Fig 1E, F and G and Table
S2). These results support the earlier observations of increase in
Figure 5. Confocal microscopy of wound edges in prostate cells. Cells were wounded and stained with phalloidin- fluorescein-5-
isothiocyanate (FITC,green) to visualize actin filaments using a Leica SP2 confocal microscope. A, B and G are untreated 1542-CP3TX, 1542-NPTX and
PC3 cells, respectively. C, D and H are AIP (10 mM) treated 1542-CP3TX, 1542-NPTX and PC3 cells, respectively. E and F are 1542-CP3TX and 1542-NPTX
treated with recombinant Wnt5A (100 ng/ml). Irregular wound leading edge and loose of intercellular connections and fine filaments of actin
(filopodia like protrusions), white arrows, are visible in 1542-NPTX normal cells and after AIP treatment in 1542-CP3TX and PC3 cancer cells. Propidium
iodide was used to stain nucleic acid (red). Scale bar=10 mm
doi:10.1371/journal.pone.0010456.g005
Wnt in Prostate Cancer
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10456the expression of Wnt5A gene in prostate cancer due to
hypomethylation [23] and also a very recent report by Yamamoto
et al [29] that used conventional, non-quantiative, histological
examination to assess Wnt5A expression prostate. This data is also
in agreement with that obtained for normal (1542-NPTX) and
cancer (1542-CP3TX) cell lines (Fig 2). Taken together the human
tissue and cell line data suggest that Wnt5A protein is expressed in
normal (or benign) tissue but its expression is dramatically
increased in malignant (cancer) prostate tissue and this change is
reflected in the cell lines used in this study.
Almost all known transcription targets activated by the Wnt/b-
catenin pathway, e.g. CTNNB1, CCCNDs, MMPs, PITX2,
CD44, APCDD1, JUN [30–32], remain unchanged or are down-
regulated in prostate cancer tissue or cell lines compared to normal
tissue or cell line (Fig. S3 and Table S1). These results indicate that
the cell line dataset largely reflects the gene expression pattern for
TCF/LEF regulated genes in both the cell line and the cancer
tissue. Furthermore, there was no increase in protein expression or
functional activity of downstream targets of canonical Wnt-
signaling (e.g. MMP-14). This suggests that 1542-NPTX and
1542-CP3TX and PC3 cell lines may be a useful model to
investigate the mechanisms of Wnt signaling in prostate cancer as
the integrity of Wnt signaling elements in prostate cancer are
preserved in these cell lines at the gene, protein and functional
levels.
CaMKII is a key mediator of Wnt/Ca
2+ signaling although a
further subset of the non-canonical Wnt signaling via Wnt5A is
proposed to be a b-catenin degradation pathway which does not
require activation of CaMKII [33]. A 3 fold increase in free
intracellular calcium concentration was observed after addition of
Wnt5A in prostate cells (Fig 3 and Movie S1). In addition, we did
not see a decrease in b-catenin protein expression and the activity
of CaMKII was found to increase in prostate cancer cell lines,
indicating that Wnt/Ca
2+ pathway was likely to be operative via
CaMKII in prostate cancer.
The multiple roles of CamKII in actin remodelling, cell motility
and migration of normal keratinocytes, muscle and nerve cells are
known [34–36]. However the involvement of CaMKII mediated
Wnt/Ca
2+ signaling in disease has been less well characterized.
Pukrop et al [37] suggested that the non-canonical pathway may be
involved in the increased migration/invasiveness of MCF7 breast
cancer cell lines when recombinant Wnt5A is added to the cell
culture. However, the mechanisms or whether Wnt5A mediated
its effect through CaMKII activation, were not investigated. Cell
motility requires two main types of actin based structures in the
cell membrane, lamellipodia and filopodia. It has been proposed,
in fibroblasts, that filopodia formation from lamellipodia is a
tightly regulated process which is partly controlled by actin
binding proteins such as enabled (Ena) / vasodilator-stimulated
phosphoprotein (VASP) capping the actin filament [38]. Fibro-
blasts move by extending lamellipodia at the leading edge and
formation of fine actin structures at the leading edge causes
retrograde movement [39]; sequestration of Ena/VASP to
mitochondria increases whereas its targeting to cell membrane
reduces motility [38]. The role of Wnt5A mediated signaling in
cell motility [37] and other intermediary proteins (e.g. Ena/VASP,
Arp2/3) in filopodia formation has been investigated in human
[14,40] and mouse [41] melanoma cells. Weeraratna and
colleagues [40] suggested that Wnt5A increased cell motility in
human melanoma cell lines by activation of protein kinase C
(PKC). Witze et al [14] showed that acute response of melanoma
cell lines to Wnt5A involves recruitment of major cytoskeletal
proteins (actin and myoxin IIB) and Frizzled 3 and melanoma cell
adhesion molecule into an intracellular structure via Wnt5A
regulation of Rab4 and RhoB guanosine triphosphatases. Another
study investigated the role for Ror2 kinase in Wnt5A induced cell
migration [42]. Unlike the data presented here, these studies
[40,42] neither investigated nor directly manipulated CaMKII
Figure 6. Scanning electron microscopy of the wound edge in
1542-CP3TX cells. Main pictures are representative images (scale bar
1 mm) of untreated (A) and AIP (10 mM) treated (B) cells. Inset is the low
magnification image (scale bar 10 mm) of the main picture. Irregular
wound edge and fine filopodia like protrusion are visible after
treatment with AIP (B, main picture). Length of filopodia like protrusions
was measured using Image J software and converted to distribution
histogram (C) for AIP treated (hollow bars) and untreated (hatched bars)
cells. An 8-fold increase in the area under the curve was observed for
treated compared to untreated cells using a Gaussian fit.
doi:10.1371/journal.pone.0010456.g006
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formation. We used tatCN21a, a specific inhibitor of CaMKII (but
not CaMKIV, PKA, PKC, MAPK1, JNK1a1, or Raf). Treatment
of prostate cancer cells with tatCN21a also caused a loosening of
cell to cell contact and induced filopodia formation (Fig. S4)
similar to the results obtained with AIP (Fig. 5). These results
indicate that direct inhibition of CaMKII (and not CaMKIV,
PKC, PKA and other kinases) results in the loss of cell to cell
contact and filopodia formation in prostate cancer cells.
In prostate cancer cell lines (1542-CP3TX and PC3) a smooth,
regular wound edge is observed with close cell to cell contact
preceding the lamellipodia like leading edge (Figs. 4 and 5). In
contrast, treatment with AIP induces an increase in filopodia like
protrusions with a loosening of cell to cell contact preceding the
wound edge (Fig. 5 and 6 and Table 1). Indeed the rate of wound
closure was decreased by 80% after inhibition of CaMKII in
cancer cell line (PC3). Conversely, addition of Wnt5A to normal
cell line (1542-NPTX) increased the rate of wound closure (mm/h)
compared to untreated cells by 2564%. We suggest that
activation of CaMKII via Wnt5A signaling is advantageous to
cancer cell mobility as it suppresses formation of fine filopodia that
induce retrograde movement thus reducing cell mobility.
Protein expression of Wnt5A in human prostate cancer and
mechanisms of Wnt signaling in normal and cancer prostate cell
lines, described here, provide the first framework within which the
exact participation of Wnt receptors and secretory frizzled related
proteins [20,21] and various actin binding proteins and interme-
diary signaling molecules such as Ena/VASP and ERK1 [34,38],
could be investigated in cancer. Further investigations to identify
the receptor(s) for Wnt5A binding and other proteins involved in
Table 1. Quantification of filopodia like projections in untreated and AIP treated 1542-CP3TX cells.
Wound edge analyzed (mm) Filopodia (all) / mm Filopodia (very long) / mm
CP - AIP 71665.02 0.1360.02 0.0460.01
CP + AIP 65068.41 0.8660.10* 0.6160.10
"
CP, prostate cancer cells (1542-CP3TX) were grown on glass coverslips, scratched/wounded and incubated with (+) or without (2) CaMKII inhibitor (10 mM, AIP) and
viewed using a scanning electron microscope. High magnification micrographs were manually analyzed (,0.7 mm of wound edge) using ImageJ software. Frequency is
represented as number of protrusions observed / mm wound length analyzed for all protrusions and a subset population of very long (.2 mm in length) filopodia like
protrusions. Both the number and frequency of projections were increased upon treatment with AIP (*
,"p,0.001). Data from 2 independent experiments is presented for
10–12 micrographs for each condition manually observed for filopodia like projections along the length of the membrane. Results are means 6 SE. Statistical analysis for
significance of difference was performed using ANOVA.
doi:10.1371/journal.pone.0010456.t001
Figure 7. Rate of wound closure and cell motility assay in PC3 cells lines by real-time cell imaging. Confluent PC3 prostate cancer cell
lines were wounded and imaged over night at 1h intervals. The images were composited (see Movies S2,control and S3, AIP) and data imported into
a spreadsheet. Addition of AIP (10 mM, hatched bar) reduced the rate of wound closure by 80% compared to control (hollow bar, * p,0.001) or
Wnt5A (100 ng/ml, solid bar). Data is presented as means 6 SE, significance of difference between control and AIP was obtained by ANOVA. Rate of
wound closure was determined by performing linear regression to calculate the slope of line (Inset, representative of n=627) for untreated control
(filled triangles, R=0.99), Wnt5A (filled squares, R=0.99) or AIP (filled circle, R=0.97) treated PC3 cells.
doi:10.1371/journal.pone.0010456.g007
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cancer will help to elucidate the novel role of CaMKII in the
suppression of filopodia formation to increase cell motility in
prostate cancer. In conclusion, from the results presented here and
our recent study [23] showing hypomethylation as a regulator of
Wnt5A gene transcription in prostate, the following sequence
could be envisaged: (i) Gene expression of Wnt5A is increased in
cancer compared to normal cells due to hypomethylation of the
gene promoter region (ii) Increase in gene expression results in
increased protein expression of Wnt5A in human prostate cancer
(iii) Wnt/Ca
2+ pathway (and not b-catenin pathway) is activated in
prostate cancer cells (iv) Signaling via Wnt/Ca
2+ pathway activates
CaMKII (v) CaMKII activity, most likely via intermediary
signaling involving actin binding proteins, causes a major
reorganization of cytoskeleton in cancer cells by decreasing the
length and frequency of fine, filopodia like actin structures. (vi)
Cytoskeletal remodeling due to CaMKII causes an increase in cell
motility. Targeting of Wnt/Ca
2+ signaling, particularly CaMKII
may provide a useful tool in prostate cancer therapy.
Materials and Methods
Cell culture
The human prostate epithelial cell line1542-NPTX and prostate
cancer cell line 1542-CP3TX [43] (derived from normal and
prostate cancer tissue from the same patient [43]) were obtained
from S L Topalian, National Cancer Institute, NIH, USA,
originators of these cell lines. Prostate carcinoma cell line PC3 was
obtained from M E Kaighn the originators of this cell line [44].
DU145 was obtained from the cell bank maintained by Jørgen
Fogh at the Sloan Kettering Cancer Center, NY, USA, from a
deposit made by the originator of this cell line [45]. PC3 and
DU145 were cultured in RPMI 1640 (Invitrogen) medium
containing 5 mM L-glutamine and fetal bovine serum (FBS) and
1542-NPTX and 1542-CP3TX were maintained in Keratinocyte-
SFM (KSFM) medium and supplements (Invitrogen) with 5% FBS
and KSFM supplements (Invitrogen).
Quantitative real time PCR
Fluorescent real-time PCR (TaqMan, Applied Biosystems, UK)
was used to verify gene expression in 1542-NPTX and 1542-
CP3TX originally identified from the microarray experiments
[23]. RNA isolation is described elsewhere [23]. TaqMan probes
and primers for real-time PCR were purchased as a pre-developed
assay system; Applied Biosystems assay IDs for the probes used
and a brief protocol is given in Table S4. Each sample was tested
in quadruplicate and results were analyzed using sequence
detector software (SDS v2.2 – Applied Biosystems, UK). Relative
quantitation was performed using the 2
2DDCT method [46].
Use of human tissue arrays for Wnt5A expression in
prostate tissue
Ethics approval. Ethical approval was given by the Joint
UCL/UCLH committees on the ethics of human research. The
review board approved the use of human tissue for prostate cancer
research, in compliance with the International Committee on
Harmonisation of Good Clinical Practice (ICH GCP). Radical
prostatectomy surgical samples, all but fivefrom the period of July
1994-April 2002, were used to construct tissue arrays (one
malignant and four benign samples from December 1991 are
also included in th analysis). The samples were anonymized during
the construction of the tissue arrays and used for various
immunohistochemical studies in a project approved by the
UCL/UCLH ethics committee. Details of patient selection,
disease state and construction details of tissue blocks are given
elsewhere [47].
Measurement and analysis of Wnt5A expression in
prostate tissue arrays
Patient selection, disease state and construction details of tissue
blocks are given elsewhere [47]. Briefly, tissue blocks were
constructed using archival formalin-fixed, paraffin-embedded
radical prostatectomy specimens from the 82 patients with
pathological state of pT3a or b and pre-operative PSA stage
of .3. All radical prostatectomy specimens were examined by a
urological pathologist. 3 mm sections were cut from the tissue
arrays onto coated slides and dried overnight at 60uC, prior to
performing standard antigen retrieval. Immunostaining was
performed using standard 3,3-diaminobenzidine staining protocol
[47] and 2 mg/ml of Wnt5A primary antibody (clone AF645,
R&D Systems) on an automated Bond maX
TM machine (Vision
BioSystems) using the Bond polymer detection system kit
(containing post primary antibodies), according to manufacturers
protocol, at high contrast (DS9173).
Image of each core was acquired with a Nikon DXM 1200
digital imaging system (image resolution=384063072 pixels)
attached to a Nikon Diaphot (20x magnification) at standardized
bright-field settings. A reproducible, automated method was
employed to quantify the DAB signal on benign and malignant
human prostate tissue cores using ImageJ software [24]. Macros
were written to execute the following sequence of events for
acquired jpeg images: 1. Open image 2. Convert to 16 bit image 3.
Set threshold (152,195) 4. Analyze particle (Size 0.5- Infinity,
Circularity 0.00–1.00). Save image 6. Save particle information
(count, total area, average size and area fraction) into an excel
spreadsheet (rsb.info.nih.gov/ij/docs/pdfs/examples.pdf). Units are de-
fault ImageJ setting (pixels). Wnt5A expression was observed to be
largely epithelial (see Figure 1); set threshold parameters were
chosen after manual analysis of random cores to quantify this
signal. A contiguous spreadsheet for all the usable cores (n= 301
malignant cores and n=299 benign cores) was constructed and
statistical analysis using Student’s t-test was performed.
Intracellular calcium imaging
PC3 cells were grown as a monolayer in 35 mm FluoroDish
(WPI). Cell growth medium was replaced with 1 ml PBS prior to
loading with calcium indicators Fluo-4 (Invitrogen) alone or in
conjunction with Fura Red (Invitrogen) at 1 ng/ml for 1 h at
37uC. Live confocal imaging was performed using an Olympus
FluoView FV 1000 confocal microscope equipped with a 20x dry
objective (numerical aperture=0.75). Calcium indicators were
excited with an argon laser line (488 nm) and emissions recorded
in the green channel (510–580 nm) for Fluo-4 and red channel
(600–700 nm) for Fura Red after addition of vehicle control (PBS)
or Wnt5A (100 ng/ml). Image and data acquisition was performed
using FluoView 1000 software (Olympus). Fluorescent intensity
was measured and data exported as a tab delimited file for further
analysis using Image J and Origin (Microcal) software. Experi-
ments were repeated in 3 different passages of cell line.
CaMKII assay
The phosphotransferase activity of CaMKII in cell lysates was
measured using the CaMKII assay kit (Upstate, UK) according to
manufacturer’s protocols. The assay is based on phosphorylation
of specific substrate peptide (KKALRRQETVDAL) by the
transfer of the c-phosphate of adenosine-59-[c-
32P]triphosphate
([c-
32P]ATP) by CaMKII.
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2+ dependent CaMKII activity is calculated as a sum of
ser/thr kinase activity in the presence of PKA/PKC inhibitors
with or without Ca
2+.
Peptides and inhibitors
CaMKII inhibitors myristoylated autocamtide-2-related inhib-
itory peptide (AIP) (Biomol, UK) and tatCN21a (a specific
inhibitor of CaMKII [28]) was purchased from the University of
Colorado, USA. Recombinant Wnt5A protein (R&D Systems,
USA) was used to activate Wnt signaling.
Wound/scratch assay and microscopy of prostate cell
lines
Cell lines (1542-NPTX, 1542-CP3TX, PC3 and DU145) were
grown on glass coverslips to confluency and scratched using a
plastic pipette tip. Details of fixing, staining and microscopy are
given in Methods S1. Rate of wound closure, as a measure of cell
motility, was determined by live cell imaging using a specialized
WoundMaker, ImageLock plates and Incucyte (Essen Instru-
ments). Wound width was photographed for 12 h, images were
composited (Movies S2, control and S3, AIP) and data saved into
an excel spreadsheet for analysis. Details are provided in Methods
S1. Statistical analysis for significance of difference was performed
using ANOVA. For scanning electron microscopy (JSM-7410
scanning electron microscope, Jeol, Japan), cells from two
independent preparations were used visualized using. Detailed
methodology is given in Methods S1.
Gene expression data analysis
We used Microarray Suite 5.0 analysis software (as described
previously, [23], GeneSpring (Agilent, UK) analysis software and
Oncomine (www.oncomine.org, [27] for the analysis of cell lines
and publicly available prostate microarray datasets.
Supporting Information
Figure S1 MMP-14 and TIMP3 expression in prostate cell lines.
MMP-14 protein expression (green) was detected at a higher level
in normal 1542-NPTX cells (A) compared to cancer 1542-CP3TX
cell line (B); scale bar = 10mm. TIMP3 protein expression (green)
was also greater in 1542-NPTX cells (C) compared to 1542-
CP3TX cancer cells (D); scale bar = 5mm. DAPI (blue) was used
to visualize the cell nuclei.
Found at: doi:10.1371/journal.pone.0010456.s001 (0.83 MB TIF)
Figure S2 Gelatin zymography of the activated MMP2 (62kDa
protein band), shows a higher level of activated MMP2 in the
MT1-MMP in normal 1542-NPTX (NP) compared to cancer
1542-CP3TX (CP) cell lines. HT1080 was used as a positive
control for the activity of MT1-MMP complex (50). A represen-
tative gel of 3 independent experiments is shown.
Found at: doi:10.1371/journal.pone.0010456.s002 (0.25 MB TIF)
Figure S3 Gene expression analysis of targets of TCF (the
nuclear mediator of Wnt/beta-catenin signaling) transcription are
downregulated in prostate cancer (A to G). Gene expression
analysis of targets of TCF: (A) APCDD1, (B) CCND1 (C) CD44,
(D) Jun, (E) Myc (F) CTNNB1 and (G) WNT5A. Box plots have
been reproduced from www.oncomine.org (see Rhodes et al,
2004), using a P-value threshold of 0.01-0.0001 for prostate cancer
v normal (non-neoplastic, normal, normal adjacent or benign
prostatic hyperplasia) tissue studies* only. Blue box = normal, red
box = cancer. All targets analyzed in cancer tissue, except c-myc,
were down-regulated in cancer compared to normal tissue. These
data are similar to those observed in 1542-NPTX v 1542-CP3TX
cell lines (derived from tissue with Gleason score 6-8, Bright et al
1997). Two other TCF targets, namely PITX2 and PLAU, did not
show a significant change in expression between cancer v normal
analysis of Yu et al, 2004 and Lapointe et al, 2004, respectively. 9
different microarray studies were used for this analysis (references
appear under each box plot). The original plots with sub-classes
can be obtained from oncomine.org.
Found at: doi:10.1371/journal.pone.0010456.s003 (0.06 MB
PDF)
Figure S4 Confocal microscopy of 1542-CP3TX wounded
prostate cancer cell line control (A) and tatCN21a (5mM) treated
(B). tatCN21a is a CamKII specific inhibitor, which does not
inhibit other kinases (e.g., CamKIV. PKA, PKC or Raf and
others). Speciific inhibition of Cam KII by tatCN21a induces fine
filopodia (arrows) and irregular wound edges compared to a
regular wound edge (arrow heads) control wounds. tatCN21a (a
peptide that specifically inhibits CamKII and not CamKIV, PKA,
PKC, Raf or MAPK1, JNK1a1, or Raf) causes disruption of cell
to cell contact and filopodia formation in prostate cancer cells
(1542CP3TX).
Found at: doi:10.1371/journal.pone.0010456.s004 (0.68 MB TIF)
Figure S5 Scanning electron microscopy of the leading wound
edge in PC3 (A and B) prostate cancer cell lines with or without
AIP treatment (scale bar = 10mm). Representative images of
untreated (A) and AIP treated (B) cells.
Found at: doi:10.1371/journal.pone.0010456.s005 (0.44 MB TIF)
Figure S6 Wound scratch assay on DU145 prostate cancer cell
line. Immunofluorescence microscopy of wounded DU145
prostate cancer cell line control (A) and AIP treated at 4h.
Inhibition of Cam KII by AIP induces irregular wound edges.
Found at: doi:10.1371/journal.pone.0010456.s006 (1.10 MB TIF)
Figure S7 Scanning electron microscopy of the leading wound
edge in LnCaP prostate cancer cell lines with (A) or without (B)
AIP treatment (scale bar = 10mm). Representative images of
untreated (A) and AIP treated (B) cells. Insets C and D are the low
magnification (scale bar = 100mm) images of LnCaP wound edge.
These results are similar to those observed for 1542-CP3TX
prostate cancer cells (Figure 6).
Found at: doi:10.1371/journal.pone.0010456.s007 (0.45 MB TIF)
Methods S1
Found at: doi:10.1371/journal.pone.0010456.s008 (0.03 MB
DOC)
Table S1 mRNA quantitation using real time PCR mRNA and
comparative CT method in prostate cell lines. 2-DDCT method
was used to calculate relative quantities of mRNA in 1542-CP3TX
relative to 1542-NPTX, using 18S rRNA as normalization
controls. A. The range is determined by evaluating the expression
2-DDCT with DDCT + s and DDCT - s, where s = SD of the
DDCT value.
Found at: doi:10.1371/journal.pone.0010456.s009 (0.03 MB
DOC)
Table S2 Quantitation of Wnt5A expression in malignant and
benign human prostate tissue using ImageJ software. DAB label,
representing Wnt5A expression was quantified in an unbiased
manner, by using a reproducible, semi-automated particle analysis
(Analyze Particles) protocol with ImageJ software. Over 600
individual prostate tissue cores (see Materials and Methods) RGB
images were converted into 16 bit grayscale (e.g., from images
shown in Fig 1). The results are mean 6 SE for the calculated
parameters of count, total area, average size and area fraction.
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DOC)
Table S3 Genes under the transcriptional regulation of Wnt/b-
catenin/TCF pathway are downregulated in the prostate cancer
cell line. Downstream targets known to be under the control of
canonical Wnt-signaling pathway are down-regulated in 1542-
CP3TX compared to 1542-NPTX cells, possibly due to the
activation of the non-canonical Wnt-signalling in these cells.
(Other Wnt/b-catenin pathway targets such as PITX2, APCDD1
or JUN did not show a significant change in expression in normal
and cancer cell lines.) Oligoarray data from Wang et al,
Oncogene, 2007 (doi: 10.1038/sj.onc.1210472).
Found at: doi:10.1371/journal.pone.0010456.s011 (0.03 MB
DOC)
Table S4 Applied Biosystems probe IDs for TaqMan assay. 18S
rRNA (Hs99999901_s1) was used as endogenous controls.
Quantitative PCR was performed using ABI Prism 7900 with
MicroFluidic cards (Applied Biosystems) according to manufac-
turer’s protocols, with each reaction containing 8ng of reverse
transcribed RNA in a 2ml reaction mix. The following cycling
parameters were employed: 48oC for 30 min, 95oC for 10 min,
followed by 40 cycles of 95oC for 15 sec and 60oC for 15 sec.
Found at: doi:10.1371/journal.pone.0010456.s012 (0.03 MB
DOC)
Movie S1 A representative time lapse imaging of Wnt5A
induced calcium release in PC3 prostate cancer cell line. Left
frame (green) for Fluo-4 in the green channel and frame on the
right (red) is for Fura red in the red channel.
Found at: doi:10.1371/journal.pone.0010456.s013 (315.40 MB
AVI)
Movie S2 Cell motility in untreated prostate cell line. Video of
wound scratch assay in control, untreated, prostate cancer cell
line. Similar videos were used for calculating the rate of wound
closure (Fig 7).
Found at: doi:10.1371/journal.pone.0010456.s014 (7.88 MB AVI)
Movie S3 Cell motility in AIP treated prostate cell line. Video of
wound scratch assay of prostate cancer cell line + AIP an inhibitor
of CamKII. Similar videos were used for calculating the rate of
wound closure (Fig 7).
Found at: doi:10.1371/journal.pone.0010456.s015 (7.20 MB AVI)
Acknowledgments
We thank D Becker and D Ciantar at the confocal microscopy core facility,
University College London, for their help. We are extremely grateful to M
Turmaine, University College London, for assistance with electron
microscopy.
Author Contributions
Conceived and designed the experiments: QW AA. Performed the
experiments: QW CAK AF JN PM AA. Analyzed the data: QW AJS
AF AA. Contributed reagents/materials/analysis tools: QW CT JM AA.
Wrote the paper: JM AA.
References
1. Nusse R, Varmus HE (1982) Many tumors induced by the mouse mammary
tumor virus contain a provirus integrated in the same region of the host genome.
Cell 31: 99–109.
2. Wodarz A, Nusse R (1998) Mechanisms of Wnt signaling in development. Annu
Rev Cell Dev Biol 14: 59–88.
3. Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin
signalling: diseases and therapies. Nat Rev Genet 5: 691–701.
4. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, et al. (2007) Wilms
tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.
Science 316: 1043–1046.
5. Iozzo RV, Eichstetter I, Danielson KG (1995) Aberrant expression of the growth
factor Wnt-5A in human malignancy. Cancer Res 55: 3495–3499.
6. Nusse R (2007) Cancer. Converging on beta-catenin in Wilms tumor. Science
316: 988–989.
7. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell
127: 469–480.
8. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, et al. (2003) The receptor
tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling
pathway. Genes Cells 8: 645–654.
9. Slusarski DC, Yang-Snyder J, Busa WB, Moon RT (1997) Modulation of
embryonic intracellular Ca2+ signaling by Wnt-5A. Dev Biol 182: 114–120.
10. Kuhl M, Sheldahl LC, Malbon CC, Moon RT (2000) Ca(2+)/calmodulin-
dependent protein kinase II is stimulated by Wnt and Frizzled homologs and
promotes ventral cell fates in Xenopus. J Biol Chem 275: 12701–12711.
11. Torres MA, Yang-Snyder JA, Purcell SM, DeMarais AA, McGrew LL, et al.
(1996) Activities of the Wnt-1 class of secreted signaling factors are antagonized
by the Wnt-5A class and by a dominant negative cadherin in early Xenopus
development. J Cell Biol 133: 1123–1137.
12. Kuhl M, Geis K, Sheldahl LC, Pukrop T, Moon RT, et al. (2001) Antagonistic
regulation of convergent extension movements in Xenopus by Wnt/beta-catenin
and Wnt/Ca2+ signaling. Mech Dev 106: 61–76.
13. Okamoto K, Narayanan R, Lee SH, Murata K, Hayashi Y (2007) The role of
CaMKII as an F-actin-bundling protein crucial for maintenance of dendritic
spine structure. Proc Natl Acad Sci U S A 104: 6418–6423.
14. Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG (2008) Wnt5a control of
cell polarity and directional movement by polarized redistribution of adhesion
receptors. Science 320: 365–369.
15. Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and
mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 5: 367–377.
16. McDonald SL, Silver A (2009) The opposing roles of Wnt-5a in cancer.
Br J Cancer 101: 209–214.
17. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008.
CA Cancer J Clin 58: 71–96.
18. Verras M, Sun Z (2006) Roles and regulation of Wnt signaling and beta-catenin
in prostate cancer. Cancer Lett 237: 22–32.
19. Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, et al. (2004) Analysis of
Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the
androgen receptor. Cancer Res 64: 7918–7926.
20. Constantinou T, Baumann F, Lacher MD, Saurer S, Friis R, et al. (2008) SFRP-4
abrogates Wnt-3a-induced beta-catenin and Akt/PKB signalling and reverses a
Wnt-3a-imposed inhibition of in vitro mammary differentiation. J Mol Signal
3: 10.
21. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, et al. (2005)
Identification of SFRP1 as a candidate mediator of stromal-to-epithelial
signaling in prostate cancer. Cancer Res 65: 10423–10430.
22. Chesire DR, Isaacs WB (2002) Ligand-dependent inhibition of beta-catenin/
TCF signaling by androgen receptor. Oncogene 21: 8453–8469.
23. Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, et al. (2007)
Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene
26: 6560–6565.
24. Rasband W (1997) ImageJ software, version.
25. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, et al.
(2009) Activated Wnt/beta-catenin signaling in melanoma is associated with
decreased proliferation in patient tumors and a murine melanoma model. Proc
Natl Acad Sci U S A 106: 1193–1198.
26. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y (2002)
Identification of membrane-type matrix metalloproteinase-1 as a target of the
beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 21:
5861–5867.
27. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004)
ONCOMINE: a cancer microarray database and integrated data-mining
platform. Neoplasia 6: 1–6.
28. Vest RS, Davies KD, O’Leary H, Port JD, Bayer KU (2007) Dual mechanism of
a natural CaMKII inhibitor. Mol Biol Cell 18: 5024–5033.
29. Yamamoto H, Oue N, Sato A, Hasegawa Y, Yamamoto H, et al. (2010) Wnt5a
signaling is involved in the aggressiveness of prostate cancer and expression of
metalloproteinase. Oncogene.
30. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, et al. (1999) Target
genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in
human colorectal carcinomas. Proc Natl Acad Sci U S A 96: 1603–1608.
31. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, et al. (2003) Wnt5a inhibits
B cell proliferation and functions as a tumor suppressor in hematopoietic tissue.
Cancer Cell 4: 349–360.
32. Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, et al. (2006) Target
genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromo-
somes Cancer 45: 565–574.
33. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, et al. (2003) Wnt-5a
inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-
catenin degradation. J Cell Biol 162: 899–908.
Wnt in Prostate Cancer
PLoS ONE | www.plosone.org 10 May 2010 | Volume 5 | Issue 5 | e1045634. Mercure MZ, Ginnan R, Singer HA (2008) CaM kinase II delta2-dependent
regulation of vascular smooth muscle cell polarization and migration.
Am J Physiol Cell Physiol 294: C1465–C1475.
35. Chernyavsky AI, Arredondo J, Marubio LM, Grando SA (2004) Differential
regulation of keratinocyte chemokinesis and chemotaxis through distinct
nicotinic receptor subtypes. J Cell Sci 117: 5665–5679.
36. Fink CC, Bayer KU, Myers JW, Ferrell JE, Jr., Schulman H, et al. (2003)
Selective regulation of neurite extension and synapse formation by the beta but
not the alpha isoform of CaMKII. Neuron 39: 283–297.
37. Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, et al. (2006) Wnt 5a
signaling is critical for macrophage-induced invasion of breast cancer cell lines.
Proc Natl Acad Sci U S A 103: 5454–5459.
38. Bear JE, Svitkina TM, Krause M, Schafer DA, Loureiro JJ, et al. (2002)
Antagonism between Ena/VASP proteins and actin filament capping regulates
fibroblast motility. Cell 109: 509–521.
39. Watanabe N, Mitchison TJ (2002) Single-molecule speckle analysis of actin
filament turnover in lamellipodia. Science 295: 1083–1086.
40. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, et al. (2002)
Wnt5a signaling directly affects cell motility and invasion of metastatic
melanoma. Cancer Cell 1: 279–288.
41. Svitkina TM, Bulanova EA, Chaga OY, Vignjevic DM, Kojima S, et al. (2003)
Mechanism of filopodia initiation by reorganization of a dendritic network. J Cell
Biol 160: 409–421.
42. Nishita M, Yoo SK, Nomachi A, Kani S, Sougawa N, et al. (2006) Filopodia
formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-
induced cell migration. J Cell Biol 175: 555–562.
43. Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, et al. (1997)
Generation and genetic characterization of immortal human prostate epithelial
cell lines derived from primary cancer specimens. Cancer Res 57: 995–1002.
44. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979)
Establishment and characterization of a human prostatic carcinoma cell line
(PC-3). Invest Urol 17: 16–23.
45. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (1978) Isolation
of a human prostate carcinoma cell line (DU 145). Int J Cancer 21: 274–281.
46. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–408.
47. Nariculam J, Freeman A, Bott S, Munson P, Cable N, et al. (2009) Utility of
tissue microarrays for profiling prognostic biomarkers in clinically localized
prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as
predictors of biochemical failure after radical prostatectomy with nested control
for clinical and pathological risk factors. Asian J Androl 11: 109–118.
Wnt in Prostate Cancer
PLoS ONE | www.plosone.org 11 May 2010 | Volume 5 | Issue 5 | e10456